ProQR Therapeutics N.V. - Ordinary Shares (PRQR): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRQR POWR Grades
- Growth is the dimension where PRQR ranks best; there it ranks ahead of 64.23% of US stocks.
- The strongest trend for PRQR is in Value, which has been heading up over the past 179 days.
- PRQR ranks lowest in Stability; there it ranks in the 4th percentile.
PRQR Stock Summary
- PRQR's price/sales ratio is 26.74; that's higher than the P/S ratio of 94.2% of US stocks.
- Revenue growth over the past 12 months for ProQR Therapeutics NV comes in at -75.5%, a number that bests only 1.63% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PRQR comes in at -187.85% -- higher than that of only 1.63% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to ProQR Therapeutics NV are CGEN, FULC, WVE, SRPT, and SURF.
- PRQR's SEC filings can be seen here. And to visit ProQR Therapeutics NV's official web site, go to www.proqr.com.
PRQR Price Target
For more insight on analysts targets of PRQR, see our PRQR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.19 | Average Broker Recommendation | 1.31 (Strong Buy) |
PRQR Stock Price Chart Interactive Chart >
PRQR Price/Volume Stats
| Current price | $0.68 | 52-week high | $9.09 |
| Prev. close | $0.81 | 52-week low | $0.53 |
| Day low | $0.68 | Volume | 734,300 |
| Day high | $0.85 | Avg. volume | 1,392,113 |
| 50-day MA | $0.71 | Dividend yield | N/A |
| 200-day MA | $4.33 | Market Cap | 48.48M |
ProQR Therapeutics N.V. - Ordinary Shares (PRQR) Company Bio
ProQR Therapeutics is a biopharmaceutical company, focused on RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. The company was founded in 2012 and is based in Leiden, the Netherlands.
Latest PRQR News From Around the Web
Below are the latest news stories about ProQR Therapeutics NV that investors may wish to consider to help them evaluate PRQR as an investment opportunity.
ProQR (PRQR) Reports Q4 Loss, Misses Revenue EstimatesProQR (PRQR) delivered earnings and revenue surprises of -15.38% and 69.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial ResultsAdditional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa underway; interim data readout from Helia extension study of ultevursen planned by year-end 2022Repeated dose study planned for QR-1123 for autosomal dominant retinitis pigmentosa and initial data from m |
Will ProQR (PRQR) Report Negative Q4 Earnings? What You Should KnowProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Why ProQR Therapeutics Stock Got Slammed Again MondayAnalysts are notably more bearish on the company following unhappy news about its leading drug candidate. |
ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III StudyProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study. |
PRQR Price Returns
| 1-mo | 6.58% |
| 3-mo | -24.03% |
| 6-mo | -91.69% |
| 1-year | -90.46% |
| 3-year | -92.69% |
| 5-year | -86.53% |
| YTD | -91.51% |
| 2021 | 90.71% |
| 2020 | -57.62% |
| 2019 | -37.20% |
| 2018 | 389.30% |
| 2017 | -34.18% |
Continue Researching PRQR
Here are a few links from around the web to help you further your research on ProQR Therapeutics NV's stock as an investment opportunity:ProQR Therapeutics NV (PRQR) Stock Price | Nasdaq
ProQR Therapeutics NV (PRQR) Stock Quote, History and News - Yahoo Finance
ProQR Therapeutics NV (PRQR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...